More ordersHALIFAX, Apr 24, 2003 (Canada NewsWire via COMTEX) --
MedMira Inc. (MedMira) (TSX Venture: MIR) announced today that it has received an additional order for 150,000 MiraWell(TM) Rapid HIV Tests from its distributor in the South Central province of Guangdong in the People's Republic of China. This follows an initial order of 250,000 units, which was announced February 13, 2003. Delivery of the second order will closely follow shipment of the first.
'Receiving this additional order for 150,000 units in such a short time following SDA approval (announced April 9, 2003) reaffirms our anticipation of the market demand for our rapid HIV test in China,'said Stephen Sham, Chairman and CEO of MedMira. 'We are extremely pleased to take such an active role in the Chinese point-of-care diagnostic industry. Chinese authorities and agencies are making extraordinary efforts to curb the spread of HIV, and we are very pleased to know that our technology can make a contribution to such a significant public health campaign.'
MedMira (www.medmira.com) is a commercial biotechnology company that develops, manufactures and markets qualitative, in vitro diagnostic tests for the detection of antibodies to certain diseases, such as HIV, in human serum, plasma or whole blood. MedMira's Reveal(TM) and MiraWell(TM) Rapid HIV Tests have recently been approved by the United States FDA and SDA in the People's Republic of China, respectively. All of MedMira's diagnostic tests are based on the same flow-through technology platform thus facilitating the development of future products. MedMira's technology provides a quick (under 3 minutes), accurate, portable, safe and cost-effective alternative to conventional laboratory testing.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
%SEDAR: 00013053E
VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: https://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=16786
For further information: PLEASE CONTACT: Dr. James Smith: (902) 450-1588, or e-mail: ir(at)medmira.com
News release via Canada NewsWire, Toronto 416-863-9350
Copyright (C) 2003 CNW, All rights reserved